Filtered By:
Cancer: Prostate Cancer
This page shows you your search results in order of relevance. This is page number 5.
Order by Relevance | Date
Total 33574 results found since Jan 2013.
Health-Related Lifestyles and Cancer-Preventive Behaviors of Medical and Nursing Students and Family Medicine Residents in Relation to the European Code Against Cancer
The objective was to evaluate the health-related lifestyles and cancer-preventive behaviors of medical and nursing students and FM residents in relation to the European Code Against Cancer (ECAC). This was a descriptive, cross-sectional study performed in Spain. Medical and nursing students and FM residents completed a self-administered questionnaire focused on health-related habits and clinical behaviors related to the ECAC. A total of 740 participants completed the questionnaire. About 12.2% (95% CI [9.8 –14.5]) were smokers, and 77.3% (95% CI [74.3–80.3]) sporadically consumed alcohol; 34.2% (95% CI [30.8–37.6]) p...
Source: Journal of Cancer Education - December 16, 2019 Category: Cancer & Oncology Source Type: research
Implementing Community-Based Prostate Cancer Education in Rural South Carolina: a Collaborative Approach Through a Statewide Cancer Alliance
In this study, education session content focused on PrCA risk factors, symptoms, screening, healthy diet and exercise, treatment options, and provider communication strategies. Forty individuals participated and completed pre/post-education program surveys to assess changes in PrCA knowledge and cancer decision-making. Participants showed improvements in education and awareness following the session, and overall impressions of the program were consistently positive as exhibited by participants ’ answers on a satisfaction survey. The findings demonstrate the real need both in terms of research to understand the underlying...
Source: Journal of Cancer Education - June 19, 2020 Category: Cancer & Oncology Source Type: research
The Genetic Education for Men (GEM) Trial: Development of Web-Based Education for Untested Men in BRCA1/2- Positive Families
AbstractCascade testing for hereditary breast/ovarian cancer is an important public health priority. Increasing attention has been paid to the relevance of testing for men withinBRCA1/2-positive families given that such testing may provide important information about their cancer risks, particularly for prostate cancer, and risks to their offspring. However, men are much less likely to seek genetic counseling and testing than their at-risk female relatives. To facilitate access to pre-test information and testing, we developed a web-based intervention (WI) for men that we are evaluating in a pilot randomized controlled tri...
Source: Journal of Cancer Education - August 10, 2019 Category: Cancer & Oncology Source Type: research
PEP Talk: Prostate Education Program, “Cutting Through the Uncertainty of Prostate Cancer for Black Men Using Decision Support Instruments in Barbershops”
The objective of this study was to investigate the effectiveness of using decision support instruments (DSI) to assist African-American (AA) men in making a prostate cancer (CaP) screening decision. This nonrandomized pretest-posttest comparison study assessed two DSI that were either culturally tailored or culturally nonspecific. CaP knowledge, intention to screen, and preferences were assessed before and after exposure to DSI using a convenience sample of 120 AA men aged 40 years and above. Participants interested in screening were referred to healthcare providers through a community-based patient navigator to obtain p...
Source: Journal of Cancer Education - July 1, 2015 Category: Cancer & Oncology Source Type: research
Complete androgen blockade vs. medical castration alone as adjuvant androgen deprivation therapy for prostate cancer patients following radical prostatectomy: a retrospective cohort study
CONCLUSION: Combined androgen blockade achieved better BCR outcomes compared with medical castration alone as adjuvant ADT for locally advanced PCa without lymph node metastasis.PMID:35234695 | DOI:10.1097/CM9.0000000000002021
Source: Chinese Medical Journal - March 2, 2022 Category: General Medicine Authors: Di Jin Kun Jin Bo Chen Xianghong Zhou Qiming Yuan Zilong Zhang Qiang Wei Shi Qiu Source Type: research
Social Appropriation of Knowledge About Research in Prostate Cancer with Middle Education Students in Three Colombian Cities
AbstractIn Colombia, prostate cancer (PCa) is the most common cancer for incidence and mortality in men, which turns it into a public health problem. For high-risk communities to better understand the usefulness of basic research about PCa, a strategy of social appropriation of knowledge (SAK) in science and cancer was designed and implemented. A pedagogical activity and two tests (a pre-test and a post-test) were applied to middle education students in four schools in three Colombian cities to identify previous knowledge of biology concepts and cancer perceptions. As for biology concepts, there was a statistically signifi...
Source: Journal of Cancer Education - October 2, 2022 Category: Cancer & Oncology Source Type: research
Philips, Profound Medical ink deal
Royal Philips (NYSE:PHG) said it signed a deal with Profound Medical to use Profound’s proprietary transurethral ultrasound ablation technology to treat prostate cancer patients in conjunction with Philips’ Ingenia and Achieva 3 tesla MRI systems.
Profounds ‘Tulsa’ system allows for a minimally invasive, whole-gland ablation of the prostate, which will be guided by Philips MRI machines, the companies said.
“Philips has stepped forward and enthusiastically shares our vision for the technology. With their support, Tulsa-Pro will soon be available to clinicians and patients for primary treatment...
Source: Mass Device - July 21, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Catheters Ultrasound Profound Medical Inc. Royal Philips Source Type: news
Profound Medical moves Plymale to COO, taps ex-Novadaq CEO Menawat | Personnel Moves August 16, 2016
Profound Medical moves Plymale to COO, taps ex-Novadaq CEO Menawat
Profound Medical said yesterday it is transitioning its current CEO Steven Plymale to the position of chief operating officer and picking up former Novadaq CEO Arun Menawat to take over the corner office.
Menawat has held a position as a board member with Profound Medical since October 2014, the company said. He joined Novadaq in 2003, and held positions at Cedara Software Corp., Tenneco, Inc. and Hercules, Inc. prior to that.
“I had the privilege of working with Arun at Cedara Software and have continued to benefit from his mentorship in the ...
Source: Mass Device - August 16, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Cardiovascular Systems Inc. Novadaq Profound Medical Inc. RTI Surgical Source Type: news
Clinical characteristics, treatment pattern, and medical costs associated with metastatic castration-resistant prostate cancer in Chinese tertiary care hospital settings.
CONCLUSIONS: Chinese mCRPC patients were characterized with delayed diagnosis of prostate cancer and high prevalence of bone metastasis. The treatment options for mCRPC were limited in Chinese patients as the conventional hormone therapy was still heavily used after the development of mCRPC. The medical costs associated with mCRPC were mainly driven by chemotherapy in Chinese patients.
PMID: 30913930 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - March 29, 2019 Category: Health Management Tags: J Med Econ Source Type: research
Impact evaluation of Swiss Medical Board reports on routine care in Switzerland: a case study of PSA screening and treatment for rupture of anterior cruciate ligament.
CONCLUSIONS: Despite some evidence of a possible change, we did not find a sustained and significant impact of SMB recommendations in our case study. Further monitoring is needed to confirm or refute these findings.
PMID: 26024476 [PubMed - as supplied by publisher]
Source: Swiss Medical Weekly - May 31, 2015 Category: Journals (General) Authors: Eichler K, Hess S, Riguzzi M, Can Ü, Brügger U Tags: Swiss Med Wkly Source Type: research
Philips, Profound Medical Collaborate On Prostate Cancer Treatment
Royal Philips and Profound Medical Corp. announced that they have signed a joint development agreement to support Profound Medical's proprietary TULSA (Transurethral Ultrasound Ablation) technology, designed to treat patients with prostate cancer on Philips' Ingenia and Achieva 3T MRI systems.
Source: Medical Design Online News - July 21, 2015 Category: Medical Equipment Source Type: news
Profound Medical wins CE Mark for Tulsa-Pro ablation device
Profound Medical said today it won CE Mark approval in the European Union for its Tulsa-Pro ablation device designed to treat prostate cancer.
The Toronto-based company’s system allows for a minimally invasive, whole-gland ablation of the prostate, guided by magnetic resonance imaging machines, the company said.
“Our innovation and passion for this unique therapy has been recognized with the achievement of CE Mark. This is a major step forward in the growth of the company, facilitating the commercial launch of Tulsa-Pro in Europe and other CE Mark jurisdictions. We expect this approval to be a catalyst for the ...
Source: Mass Device - April 11, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Catheters Regulatory/Compliance Ultrasound Profound Medical Inc. Source Type: news
Philips and Profound Medical extend ablation tech deal
Royal Philips (NYSE:PHG) said it extended its deal with Profound Medical to include a sales and marketing agreement to promote Profounds’ Tulsa-Pro ultrasound ablation system.
Profounds Tulsa system allows for a minimally invasive, whole-gland ablation of the prostate, which will be guided by Philips MRI machines, the companies said.
“Our agreement with Philips will enable us to increase our reach of this unique technology to more clinicians and their patients requiring prostate care. I am convinced that our Tulsa technology will be a valuable addition to Philips’ expanding interventional oncology portfolio...
Source: Mass Device - May 17, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Catheters Ultrasound Urology Profound Medical Inc. Royal Philips Source Type: news
Medical hospitalizations in prostate cancer survivors
The objectives of the study were to explore the context and reasons for medical hospitalizations among prostate cancer survivors and to study their relationship with obesity and the type of prostate cancer treatment. A retrospective review of medical records was performed at an academic institution for male patients aged 40 years and older who were diagnosed and/or treated for prostate cancer 2 years prior to the study’s observation period from January 2008 to December 2010. Unpaired t test, ANOVA, and Chi-square tests were used to compare patients’ characteristics, admission types, and medical comorbidities by body ...
Source: Medical Oncology - June 19, 2016 Category: Cancer & Oncology Source Type: research
The application of p2PSA% and prostate health index in prostate cancer detection: A prospective cohort in a Tertiary Medical Center
Conclusion %p2PSA and PHI increased the diagnostic accuracy with significantly greater sensitivity and specificity than tPSA. We determined an optimal cut-off value of PHI among Taiwanese population. These findings support the usefulness in the decisional process of prostate biopsy.
Source: Journal of the Formosan Medical Association - May 18, 2018 Category: General Medicine Source Type: research
